We discovered that inhibiting SPP1 reversed the tumor progression and extended survival times caused by the overexpression of CEBPB in vivo (Figure 8J-K), which was associated to change the number of SPP1/Integrin αvβ1/phosphorylated-Akt-positive M2 TAMs in the xenograft tumors (Figure 8L-M, Figure S16). This evidence concerns the gene CEBPB and neoplasm.